X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
FLX475 (tivumecirnon) is a small molecule CCR4 antagonist, is being evaluated with Pembrolizumab for the treatment of advanced head and neck squamous cell carcinoma.
Lead Product(s): Tivumecirnon,Pembrolizumab
Therapeutic Area: Oncology Product Name: FLX475
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2024
Details:
RPT193 (zelnecirnon) is an antagonist of CCR4 receptor that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17. It is being evaluated for the treatment of atopic dermatitis.
Lead Product(s): Zelnecirnon
Therapeutic Area: Dermatology Product Name: RPT193
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
FLX475 (tivumecirnon), an oral small molecule CCR4 antagonist designed to block the migration of regulatory T cells, in combination with the checkpoint inhibitor pembrolizumab for pateint with NSCLC.
Lead Product(s): Tivumecirnon,Pembrolizumab
Therapeutic Area: Oncology Product Name: FLX475
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2023
Details:
RPT193 is a small molecule, CCR4 antagonist designed to selectively inhibit the migration of Th2 cells into inflamed tissues In allergic inflammatory diseases such as atopic dermatitis and asthma.
Lead Product(s): Zelnecirnon
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RPT193
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Details:
FLX475 is a small molecule CCR4 antagonist designed to block the migration of regulatory T cells (Treg) specifically into tumors, but not healthy tissues. Treg represent a dominant pathway for downregulating the immune response.
Lead Product(s): Tivumecirnon,Pembrolizumab
Therapeutic Area: Oncology Product Name: FLX475
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
FLX475 is a small molecule CCR4 antagonist designed to block the migration of regulatory T cells (Treg) specifically into tumors, but not healthy tissues, without depleting Treg throughout the body which may decrease the likelihood of side effects.
Lead Product(s): Tivumecirnon,Pembrolizumab
Therapeutic Area: Oncology Product Name: FLX475
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
RPT193 is an orally-administered small molecule CCR4 antagonist that blocks the recruitment of inflammatory immune cells, known as Th2 cells, which are clinically implicated in a broad range of inflammatory disorders.
Lead Product(s): Zelnecirnon
Therapeutic Area: Dermatology Product Name: RPT193
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 17, 2022
Details:
In a post-hoc statistical analysis comparing RPT193-treated patients to placebo-treated patients, the improvements in EASI, EASI-50 and BSA at Day 43 were statistically significant. RPT193 was well tolerated in the Phase 1b study.
Lead Product(s): Zelnecirnon
Therapeutic Area: Dermatology Product Name: RPT193
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Details:
The biomarker data, showed patients treated with RPT193 experienced a statistically significant improvement (p<0.001) in the meta-analysis derived atopic dermatitis (MADAD) score, a well-established gene signature that tracks with disease severity.
Lead Product(s): Zelnecirnon
Therapeutic Area: Dermatology Product Name: RPT193
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
RPT193 is a small molecule CCR4 antagonist that blocks the recruitment of inflammatory immune cells, known as Th2 cells, which are clinically implicated in allergic inflammatory disorders, such as atopic dermatitis.
Lead Product(s): Zelnecirnon
Therapeutic Area: Dermatology Product Name: RPT193
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
